US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
HUE055817T2
(en)
|
2009-07-08 |
2021-12-28 |
Kymab Ltd |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
US9457079B2
(en)
|
2010-05-12 |
2016-10-04 |
The Trustees Of Columbia University In The City Of New York |
Methods for producing enteroendocrine cells that make and secrete insulin
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
WO2013163394A1
(en)
|
2012-04-25 |
2013-10-31 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
WO2013169382A1
(en)
*
|
2012-05-07 |
2013-11-14 |
DePuy Synthes Products, LLC |
Methods and devices for treating intervertebral disc disease
|
PT2800811T
(en)
|
2012-05-25 |
2017-08-17 |
Univ California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
HUE030799T2
(en)
|
2012-07-11 |
2017-06-28 |
Sangamo Biosciences Inc |
Methods and compositions for the treatment of lysosomal storage diseases
|
CN110643600A
(en)
|
2012-10-23 |
2020-01-03 |
基因工具股份有限公司 |
System for cutting target DNA and use thereof
|
ES2769310T3
(en)
|
2012-12-06 |
2020-06-25 |
Sigma Aldrich Co Llc |
Modification and regulation of the genome based on CRISPR
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
EP2931892B1
(en)
|
2012-12-12 |
2018-09-12 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
MX2015007550A
(en)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications.
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
SG10201912327SA
(en)
|
2012-12-12 |
2020-02-27 |
Broad Inst Inc |
Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
EP3825401A1
(en)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
EP3553174A1
(en)
*
|
2012-12-17 |
2019-10-16 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
WO2014113493A1
(en)
*
|
2013-01-16 |
2014-07-24 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
ES2901396T3
(en)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Nucleic Acid Targeting Nucleic Acid Compositions and Methods
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
CN110540991B
(en)
*
|
2013-03-15 |
2023-10-24 |
通用医疗公司 |
Enhancement of specificity of RNA-guided genome editing using truncated guide RNA (tru-gRNA)
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2014165349A1
(en)
*
|
2013-04-04 |
2014-10-09 |
Trustees Of Dartmouth College |
Compositions and methods for in vivo excision of hiv-1 proviral dna
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
JP6411463B2
(en)
|
2013-04-16 |
2018-10-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
CN116083487A
(en)
*
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
Methods and compositions for treating genetic conditions
|
JP7065564B2
(en)
*
|
2013-05-29 |
2022-05-12 |
セレクティス |
Methods for Providing Accurate DNA Cleavage Using CAS9 Nickase Activity
|
MY177814A
(en)
*
|
2013-06-04 |
2020-09-23 |
Harvard College |
Rna-guided transcriptional regulation
|
US9267135B2
(en)
*
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
EP3011034B1
(en)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
CN105492611A
(en)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation
|
RU2716420C2
(en)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver
|
JP2016528890A
(en)
*
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Therapeutic use of genome editing using the CRISPR / Cas system
|
BR112016000571B1
(en)
|
2013-07-10 |
2023-12-26 |
President And Fellows Of Harvard College |
IN VITRO METHODS FOR MODULATING EXPRESSION AND FOR ALTERING ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL SIMULTANEOUSLY WITH REGULATING THE EXPRESSION OF ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL AS WELL AS A YEAST OR BACTERIAL CELL COMPRISING NUCLEIC ACIDS
|
EP3971287A1
(en)
*
|
2013-07-11 |
2022-03-23 |
ModernaTX, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
US9663782B2
(en)
*
|
2013-07-19 |
2017-05-30 |
Larix Bioscience Llc |
Methods and compositions for producing double allele knock outs
|
US10563225B2
(en)
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
MX2016002118A
(en)
|
2013-08-22 |
2016-06-28 |
Du Pont |
Plant genome modification using guide rna/cas endonuclease systems and methods of use.
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9925248B2
(en)
|
2013-08-29 |
2018-03-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
WO2015040402A1
(en)
*
|
2013-09-18 |
2015-03-26 |
Kymab Limited |
Methods. cells & organisms
|
TW201546284A
(en)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
Animal models and therapeutic molecules
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
CA2930877A1
(en)
*
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
EP3460063B1
(en)
|
2013-12-11 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
RU2685914C1
(en)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Methods and compositions for genome targeted modification
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
CN106536729A
(en)
*
|
2013-12-12 |
2017-03-22 |
布罗德研究所有限公司 |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
CN105899657A
(en)
|
2013-12-12 |
2016-08-24 |
布罗德研究所有限公司 |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
MX2016007328A
(en)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing.
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
KR20160089530A
(en)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
AU2014362248A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
ES2787198T3
(en)
*
|
2014-01-31 |
2020-10-15 |
Factor Bioscience Inc |
Synthetic RNA for use in the treatment of dystrophic epidermolysis bullosa
|
PL3105328T3
(en)
|
2014-02-11 |
2020-10-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Crispr enabled multiplexed genome engineering
|
MX2016010781A
(en)
|
2014-02-18 |
2017-02-15 |
Univ Duke |
Compositions for the inactivation of virus replication and methods of making and using the same.
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
JP2017508457A
(en)
|
2014-02-27 |
2017-03-30 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
T cell balance gene expression, composition and method of use thereof
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
EP3140403A4
(en)
*
|
2014-05-09 |
2017-12-20 |
Université Laval |
Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
|
WO2015178343A1
(en)
*
|
2014-05-20 |
2015-11-26 |
国立大学法人北海道大学 |
LIPID MEMBRANE STRUCTURE FOR siRNA INTRACELLULAR DELIVERY
|
EP3712254A1
(en)
|
2014-05-28 |
2020-09-23 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
WO2015184268A1
(en)
*
|
2014-05-30 |
2015-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
PL3152312T3
(en)
|
2014-06-06 |
2020-08-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for modifying a targeted locus
|
EP3157573A4
(en)
|
2014-06-19 |
2018-02-21 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
AU2015280069B2
(en)
|
2014-06-23 |
2021-08-12 |
The General Hospital Corporation |
Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
|
PT3155099T
(en)
*
|
2014-06-23 |
2018-04-20 |
Regeneron Pharma |
Nuclease-mediated dna assembly
|
WO2015200901A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
MX2016017317A
(en)
|
2014-06-26 |
2017-08-24 |
Regeneron Pharma |
Methods and compositions for targeted genetic modifications and methods of use.
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
US10081816B1
(en)
*
|
2014-07-03 |
2018-09-25 |
Nant Holdings Ip, Llc |
Mechanical transfection devices and methods
|
US10760040B1
(en)
|
2014-07-03 |
2020-09-01 |
NanoCav, LLC |
Mechanical transfection devices and methods
|
EP2966170A1
(en)
*
|
2014-07-10 |
2016-01-13 |
Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - |
HBV inactivation
|
AU2015288157A1
(en)
|
2014-07-11 |
2017-01-19 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
CN106795524A
(en)
*
|
2014-07-11 |
2017-05-31 |
先锋国际良种公司 |
Change agronomy character and its application method using guide RNA/CAS endonuclease systems
|
AU2015289656A1
(en)
|
2014-07-16 |
2017-02-16 |
Modernatx, Inc. |
Circular polynucleotides
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
US9850521B2
(en)
*
|
2014-08-01 |
2017-12-26 |
Agilent Technologies, Inc. |
In vitro assay buffer for Cas9
|
WO2016025469A1
(en)
*
|
2014-08-11 |
2016-02-18 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
|
WO2016025759A1
(en)
*
|
2014-08-14 |
2016-02-18 |
Shen Yuelei |
Dna knock-in system
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
EP3186376B1
(en)
|
2014-08-27 |
2019-03-20 |
Caribou Biosciences, Inc. |
Methods for increasing cas9-mediated engineering efficiency
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
CN108064129A
(en)
|
2014-09-12 |
2018-05-22 |
纳幕尔杜邦公司 |
The generation in the site-specific integration site of complex character locus and application method in corn and soybean
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016049024A2
(en)
*
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
CN104293831A
(en)
*
|
2014-09-28 |
2015-01-21 |
上海云舜生物技术有限公司 |
Method for establishing hypertension mouse model and application of hypertension mouse model
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
WO2016057850A1
(en)
|
2014-10-09 |
2016-04-14 |
Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
US20170354745A1
(en)
*
|
2014-10-09 |
2017-12-14 |
The Regents Of The University Of California |
Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
|
CA2964114A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Anthrogenesis Corporation |
Placenta-derived adherent cell exosomes and uses thereof
|
US10428310B2
(en)
|
2014-10-15 |
2019-10-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
CN107208086A
(en)
|
2014-10-17 |
2017-09-26 |
霍华德休斯医学研究所 |
genomic probe
|
US11584916B2
(en)
|
2014-10-17 |
2023-02-21 |
Children's Hospital Medical Center |
Method of making in vivo human small intestine organoids from pluripotent stem cells
|
RU2738421C2
(en)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Versions of recombinant aav and use thereof
|
US20170247762A1
(en)
|
2014-10-27 |
2017-08-31 |
The Board Institute Inc. |
Compositions, methods and use of synthetic lethal screening
|
WO2016069910A1
(en)
|
2014-10-29 |
2016-05-06 |
Massachusetts Eye And Ear Infirmary |
Methods for efficient delivery of therapeutic molecules in vitro and in vivo
|
JP6788584B2
(en)
*
|
2014-10-31 |
2020-11-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
Massively Parallel Combinatorial Genetics on CRISPR
|
RU2020109343A
(en)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
AADC POLINUCLEOTIDES FOR TREATMENT OF PARKINSON'S DISEASE
|
US11680268B2
(en)
|
2014-11-07 |
2023-06-20 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
MX2017006216A
(en)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als).
|
DK3218386T3
(en)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
MODULATORY POLYNUCLEOTID
|
KR102531016B1
(en)
|
2014-11-21 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
|
US11168369B2
(en)
|
2014-11-25 |
2021-11-09 |
The Brigham And Women's Hospital, Inc. |
Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
|
US20180057839A1
(en)
|
2014-11-26 |
2018-03-01 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3227447B1
(en)
|
2014-12-03 |
2024-04-24 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
EP3230452A1
(en)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094880A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
RU2707137C2
(en)
|
2014-12-19 |
2019-11-22 |
Регенерон Фармасьютикалз, Инк. |
Methods and compositions for targeted genetic modification by single-step multiple targeting
|
WO2016100857A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
EP3400953A1
(en)
|
2014-12-23 |
2018-11-14 |
4D Pharma Research Limited |
Pirin polypeptide and immune modulation
|
KR102523805B1
(en)
|
2014-12-23 |
2023-04-20 |
4디 파마 리서치 리미티드 |
Immune modulation
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
WO2016109840A2
(en)
|
2014-12-31 |
2016-07-07 |
Synthetic Genomics, Inc. |
Compositions and methods for high efficiency in vivo genome editing
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
US10059940B2
(en)
*
|
2015-01-27 |
2018-08-28 |
Minghong Zhong |
Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
|
ES2955957T3
(en)
|
2015-01-28 |
2023-12-11 |
Caribou Biosciences Inc |
CRISPR hybrid DNA/RNA polynucleotides and procedures for use
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
US10584321B2
(en)
*
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
WO2016138488A2
(en)
|
2015-02-26 |
2016-09-01 |
The Broad Institute Inc. |
T cell balance gene expression, compositions of matters and methods of use thereof
|
US11261466B2
(en)
|
2015-03-02 |
2022-03-01 |
Sinai Health System |
Homologous recombination factors
|
EP3265559B1
(en)
|
2015-03-03 |
2021-01-06 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
CN104673816A
(en)
*
|
2015-03-05 |
2015-06-03 |
广东医学院 |
PCr-NHEJ (non-homologous end joining) carrier as well as construction method of pCr-NHEJ carrier and application of pCr-NHEJ carrier in site-specific knockout of bacterial genes
|
CN106032540B
(en)
*
|
2015-03-16 |
2019-10-25 |
中国科学院上海生命科学研究院 |
Gland relevant viral vector building of CRISPR/Cas9 endonuclease enzyme system and application thereof
|
GB2536650A
(en)
|
2015-03-24 |
2016-09-28 |
Augmedics Ltd |
Method and system for combining video-based and optic-based augmented reality in a near eye display
|
US20180066253A1
(en)
*
|
2015-03-26 |
2018-03-08 |
Yale University |
Methods and compositions for modifying endothelial cells
|
EP3553178A1
(en)
|
2015-03-27 |
2019-10-16 |
E. I. du Pont de Nemours and Company |
Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
|
WO2016161260A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Agenovir Corporation |
Gene delivery methods and compositions
|
ES2959608T3
(en)
*
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composition and editing methods of the B cell genome
|
JP6873911B2
(en)
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
In vitro methods to induce gene regulation of target nucleic acids in primary cells
|
GB201506509D0
(en)
|
2015-04-16 |
2015-06-03 |
Univ Wageningen |
Nuclease-mediated genome editing
|
CN107690480B
(en)
|
2015-04-24 |
2022-03-22 |
爱迪塔斯医药公司 |
Evaluation of CAS9 molecule/guide RNA molecule complexes
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016187717A1
(en)
*
|
2015-05-26 |
2016-12-01 |
Exerkine Corporation |
Exosomes useful for genome editing
|
CA3000155A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
UY36703A
(en)
|
2015-06-02 |
2016-12-30 |
Monsanto Technology Llc |
COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT
|
CN108368502B
(en)
|
2015-06-03 |
2022-03-18 |
内布拉斯加大学董事委员会 |
DNA editing using single-stranded DNA
|
GB201509578D0
(en)
*
|
2015-06-03 |
2015-07-15 |
Univ Singapore |
Vectors
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
PT3240554T
(en)
|
2015-06-15 |
2019-11-04 |
4D Pharma Res Ltd |
Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
|
MA41060B1
(en)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
DK3206700T3
(en)
|
2015-06-15 |
2019-08-05 |
4D Pharma Res Ltd |
COMPOSITIONS COMPREHENSIVE BAKERY STUES
|
PT3307288T
(en)
|
2015-06-15 |
2019-10-17 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
MA41010B1
(en)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
US10648020B2
(en)
|
2015-06-18 |
2020-05-12 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
EP3800255A3
(en)
*
|
2015-06-18 |
2021-06-23 |
Robert D. Bowles |
Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
|
EP3666895A1
(en)
|
2015-06-18 |
2020-06-17 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
RU2752834C2
(en)
|
2015-06-18 |
2021-08-09 |
Те Брод Инститьют, Инк. |
Crispr enzyme mutations reducing non-targeted effects
|
EP3316159A4
(en)
|
2015-06-25 |
2019-08-14 |
Advanced Telecommunications Research Institute International |
Prediction device based on multiple organ-related system and prediction program
|
EP3313416A4
(en)
*
|
2015-06-26 |
2019-02-20 |
The Trustees of Columbia University in the City of New York |
Genetically modified ips cells that carry a marker to report expression of neurogenin3, tph2, foxo1 and/or insulin genes
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
US10456452B2
(en)
|
2015-07-02 |
2019-10-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US20180360994A1
(en)
*
|
2015-07-25 |
2018-12-20 |
Habib Frost |
System, device and a method for providing a therapy or a cure for cancer and other pathological states
|
WO2017019867A1
(en)
*
|
2015-07-28 |
2017-02-02 |
Danisco Us Inc |
Genome editing systems and methods of use
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
CN108472314A
(en)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
The cell and therapy of modification
|
EP3334746B1
(en)
|
2015-08-14 |
2021-11-24 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
CA2996001A1
(en)
*
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
WO2017040348A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
IL241462A0
(en)
|
2015-09-10 |
2015-11-30 |
Yeda Res & Dev |
Heterologous engineering of betalain pigments in plants
|
AU2016319110B2
(en)
|
2015-09-11 |
2022-01-27 |
The General Hospital Corporation |
Full interrogation of nuclease DSBs and sequencing (FIND-seq)
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
JP2018529353A
(en)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq)
|
WO2017062754A1
(en)
*
|
2015-10-07 |
2017-04-13 |
New York University |
Compositions and methods for enhancing crispr activity by polq inhibition
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
EP3365441A1
(en)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
IL294014B1
(en)
|
2015-10-23 |
2024-03-01 |
Harvard College |
Nucleobase editors and uses thereof
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US11092607B2
(en)
|
2015-10-28 |
2021-08-17 |
The Board Institute, Inc. |
Multiplex analysis of single cell constituents
|
WO2017075294A1
(en)
|
2015-10-28 |
2017-05-04 |
The Board Institute Inc. |
Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
|
AU2016349288A1
(en)
|
2015-11-03 |
2018-05-31 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
US20180327781A1
(en)
*
|
2015-11-09 |
2018-11-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Novel rna-based vector system for transient and stable gene expression
|
WO2017083722A1
(en)
*
|
2015-11-11 |
2017-05-18 |
Greenberg Kenneth P |
Crispr compositions and methods of using the same for gene therapy
|
EP3374502B1
(en)
|
2015-11-13 |
2021-10-27 |
Avellino Lab USA, Inc. |
Methods for the treatment of corneal dystrophies
|
EP3377042A4
(en)
|
2015-11-16 |
2019-05-29 |
The Research Institute at Nationwide Children's Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopaties
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
KR101914245B1
(en)
|
2015-11-20 |
2018-11-02 |
4디 파마 리서치 리미티드 |
Composition Containing Bacterial Strain
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
JP2019500899A
(en)
|
2015-11-23 |
2019-01-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Cellular RNA tracking and manipulation through nuclear delivery of CRISPR / Cas9
|
US20210395799A1
(en)
*
|
2015-11-25 |
2021-12-23 |
Integrated Dna Technologies, Inc. |
Methods for variant detection
|
US20170145486A1
(en)
*
|
2015-11-25 |
2017-05-25 |
Integrated Dna Technologies, Inc. |
Methods for variant detection
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CN105624191A
(en)
*
|
2015-12-24 |
2016-06-01 |
江苏大学 |
Method for establishing CYP2D1 gene knockout rat model
|
CN105624196A
(en)
*
|
2015-12-24 |
2016-06-01 |
江苏大学 |
Method for establishing CYP2C11 gene knockout rat model
|
CN105548420B
(en)
*
|
2015-12-30 |
2019-08-02 |
上海泽润生物科技有限公司 |
The detection method of MOPS residual quantity
|
ES2944597T3
(en)
|
2015-12-30 |
2023-06-22 |
Novartis Ag |
Enhanced Efficacy Immune Effector Cell Therapies
|
US9856497B2
(en)
|
2016-01-11 |
2018-01-02 |
The Board Of Trustee Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
MX2018008345A
(en)
|
2016-01-11 |
2018-12-06 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of immunotherapy.
|
US10053693B2
(en)
|
2016-01-19 |
2018-08-21 |
Mubin I. Syed |
Method for controlling obesity using minimally invasive means
|
JP6914274B2
(en)
|
2016-01-22 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Crystal structure of CRISPRCPF1
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
EP4094780A3
(en)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
AU2017219605B2
(en)
*
|
2016-02-15 |
2023-04-13 |
Temple University - Of The Commonwealth System Of Higher Education |
Excision of retroviral nucleic acid sequences
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
CN116763942A
(en)
|
2016-02-18 |
2023-09-19 |
宾州研究基金会 |
Intra-brain generation of GABAergic neurons
|
US20190144942A1
(en)
|
2016-02-22 |
2019-05-16 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating immune phenotypes
|
US10286073B2
(en)
*
|
2016-02-23 |
2019-05-14 |
Ilisa Tech, Inc. |
Magnetic control of gene delivery in vivo
|
CN114908093A
(en)
*
|
2016-02-26 |
2022-08-16 |
朗泽科技新西兰有限公司 |
CRISPR/CAS system for C1 immobilized bacteria
|
MA42560B1
(en)
|
2016-03-04 |
2019-07-31 |
4D Pharma Plc |
Compositions comprising bacterial strains of blautia for the treatment of visceral hypersensitivity
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
US11427861B2
(en)
|
2016-03-17 |
2022-08-30 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
WO2017170803A1
(en)
*
|
2016-03-29 |
2017-10-05 |
株式会社国際電気通信基礎技術研究所 |
Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
|
JP7245651B2
(en)
*
|
2016-03-30 |
2023-03-24 |
インテリア セラピューティクス,インコーポレイテッド |
Lipid Nanoparticle Formulations for CRISPR/CAS Components
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
KR102670601B1
(en)
*
|
2016-04-19 |
2024-05-29 |
더 브로드 인스티튜트, 인코퍼레이티드 |
The novel CRISPR enzyme and system
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2017189525A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
WO2017189542A1
(en)
*
|
2016-04-26 |
2017-11-02 |
University Of Georgia Research Foundation, Inc. |
Plants having reduced methylation of cytosine nucleotides and methods of use
|
WO2017190091A1
(en)
|
2016-04-29 |
2017-11-02 |
Vindico Nanobiotechnology, Llc |
Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
EP4177335A1
(en)
|
2016-05-05 |
2023-05-10 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
EP3457840B1
(en)
|
2016-05-20 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
US11788083B2
(en)
|
2016-06-17 |
2023-10-17 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
EP3474849A4
(en)
|
2016-06-27 |
2020-07-29 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
TW201821093A
(en)
|
2016-07-13 |
2018-06-16 |
英商4D製藥有限公司 |
Compositions comprising bacterial strains
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
WO2018021855A1
(en)
*
|
2016-07-28 |
2018-02-01 |
기초과학연구원 |
Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
|
EP3490373B1
(en)
|
2016-07-29 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
AU2017305404B2
(en)
|
2016-08-02 |
2023-11-30 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290 associated disease
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
RU2022103870A
(en)
*
|
2016-08-12 |
2022-03-04 |
Тулджен Инкорпорейтед |
MODIFIED IMMUNOREGULATORY ELEMENT AND CHANGE OF IMMUNE THROUGH THIS ELEMENT
|
US20200283743A1
(en)
*
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2018035503A1
(en)
*
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
WO2018039145A1
(en)
|
2016-08-20 |
2018-03-01 |
Avellino Lab Usa, Inc. |
Single guide rna, crispr/cas9 systems, and methods of use thereof
|
US20220056440A1
(en)
*
|
2016-08-20 |
2022-02-24 |
Tara Moore |
Crispr gene editing for autosomal dominant diseases
|
WO2020225754A1
(en)
|
2019-05-06 |
2020-11-12 |
Mcmullen Tara |
Crispr gene editing for autosomal dominant diseases
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
IL247752A0
(en)
|
2016-09-11 |
2016-11-30 |
Yeda Res & Dev |
Compositions and methods for regulating gene expression for targeted mutagenesis
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
CN109715804A
(en)
*
|
2016-09-23 |
2019-05-03 |
帝斯曼知识产权资产管理有限公司 |
Guide RNA expression system for host cell
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
AU2017335890B2
(en)
|
2016-09-30 |
2024-05-09 |
The Regents Of The University Of California |
RNA-guided nucleic acid modifying enzymes and methods of use thereof
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
CN110462034A
(en)
*
|
2016-10-07 |
2019-11-15 |
综合Dna技术公司 |
Streptococcus pyogenes CAS9 mutated gene and polypeptide encoded by it
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
KR20190075964A
(en)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
AAV capsid design
|
CN110214180A
(en)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
The AAV of nucleobase editing machine is delivered
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
AU2017346885B2
(en)
|
2016-10-18 |
2021-10-21 |
Intima Bioscience, Inc. |
Tumor infiltrating lymphocytes and methods of therapy
|
CA3041517A1
(en)
|
2016-10-19 |
2018-04-26 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
AU2017358122B2
(en)
*
|
2016-11-14 |
2022-12-22 |
Toolgen Incorporated |
Artificially engineered SC function control system
|
SG10202105768WA
(en)
|
2016-12-05 |
2021-06-29 |
Childrens Hospital Med Ct |
Colonic organoids and methods of making and using same
|
PT3551753T
(en)
|
2016-12-09 |
2022-09-02 |
Harvard College |
Crispr effector system based diagnostics
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
KR20210035022A
(en)
|
2016-12-14 |
2021-03-31 |
리간달 인코포레이티드 |
Compositions and methods for delivery of nucleic acid and/or protein loads
|
GB2605925B
(en)
*
|
2016-12-23 |
2023-02-22 |
Harvard College |
Gene editing of PCSK9
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11733235B2
(en)
|
2016-12-27 |
2023-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Method for evaluating immunogenicity of test substance
|
CN106632693B
(en)
*
|
2017-01-19 |
2021-05-25 |
上海科技大学 |
SpyCas9 protein with multiple nuclear localization sequences and application thereof
|
KR102619197B1
(en)
|
2017-01-23 |
2024-01-03 |
리제너론 파마슈티칼스 인코포레이티드 |
HSD17B13 variant and its uses
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
WO2018147343A1
(en)
*
|
2017-02-07 |
2018-08-16 |
Edigene Corporation |
Method of treating diseases associated with elevated kras expression using crispr-gndm system
|
WO2018152418A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
|
EP3589751A4
(en)
*
|
2017-03-03 |
2021-11-17 |
The Regents of The University of California |
RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
|
US10687520B2
(en)
|
2017-03-07 |
2020-06-23 |
The Board Of Regents Of The University Of Texas System |
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(en)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Base-editing factor from cytosine to guanine
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
EP3596207B1
(en)
|
2017-03-15 |
2023-12-20 |
The Broad Institute, Inc. |
Novel cas13b orthologues crispr enzymes and systems
|
US11104937B2
(en)
|
2017-03-15 |
2021-08-31 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics
|
US11174515B2
(en)
|
2017-03-15 |
2021-11-16 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics
|
CN111108220A
(en)
|
2017-03-15 |
2020-05-05 |
博德研究所 |
CRISPR-Effector System-based diagnostics for Virus detection
|
US20200115753A1
(en)
|
2017-03-17 |
2020-04-16 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
CA3057330A1
(en)
*
|
2017-03-21 |
2018-09-27 |
Anthony P. Shuber |
Treating cancer with cas endonuclease complexes
|
MX2019011272A
(en)
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Compositions and methods for immunooncology.
|
KR20190130613A
(en)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Nucleobase edits comprising nucleic acid programmable DNA binding proteins
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
US11618928B2
(en)
|
2017-04-12 |
2023-04-04 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics for malaria detection
|
KR20200006054A
(en)
|
2017-04-12 |
2020-01-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
New Type VI CRISPR Orthologs and Systems
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
US11913015B2
(en)
|
2017-04-17 |
2024-02-27 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
EP3612629A1
(en)
|
2017-04-18 |
2020-02-26 |
The Broad Institute, Inc. |
Compositions for detecting secretion and methods of use
|
EP3612551A4
(en)
|
2017-04-21 |
2020-12-30 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
US11696954B2
(en)
*
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
US11072816B2
(en)
|
2017-05-03 |
2021-07-27 |
The Broad Institute, Inc. |
Single-cell proteomic assay using aptamers
|
CN110913866A
(en)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS)
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
US20210278416A1
(en)
|
2017-05-09 |
2021-09-09 |
The Broad Institute, Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
AU2018265022A1
(en)
|
2017-05-10 |
2019-11-21 |
The Regents Of The University Of California |
Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
KR102607330B1
(en)
*
|
2017-05-16 |
2023-11-28 |
위스콘신 얼럼나이 리서어치 화운데이션 |
Systems and methods for batch patterning of molecular structures
|
JP7364472B2
(en)
|
2017-05-18 |
2023-10-18 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Systems, methods, and compositions for targeted nucleic acid editing
|
TW201907928A
(en)
|
2017-05-22 |
2019-03-01 |
英商4D製藥研究有限公司 |
a composition comprising a bacterial strain
|
MA41708A
(en)
|
2017-05-24 |
2020-04-08 |
4D Pharma Res Ltd |
COMPOSITIONS CONTAINING BACTERIAL STRAINS
|
JP2020521446A
(en)
|
2017-05-25 |
2020-07-27 |
ザ ジェネラル ホスピタル コーポレイション |
Bipartite base editor (BBE) structure and type II-C-CAS9 zinc finger editing
|
WO2018226762A1
(en)
|
2017-06-05 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
|
AU2018279829B2
(en)
|
2017-06-09 |
2024-01-04 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
ES2841902T3
(en)
|
2017-06-14 |
2021-07-12 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
MA49425A
(en)
|
2017-06-14 |
2020-04-22 |
4D Pharma Res Ltd |
COMPOSITIONS CONTAINING BACTERIAL STRAINS
|
JOP20190269A1
(en)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
WO2018237107A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Kentucky Research Foundation |
Method
|
WO2019005884A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
CN110869031A
(en)
*
|
2017-06-28 |
2020-03-06 |
南佛罗里达大学 |
Modified UBE3A gene for use in methods of gene therapy for Angel syndrome
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
US20200140896A1
(en)
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
US11168322B2
(en)
|
2017-06-30 |
2021-11-09 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
JP7210028B2
(en)
*
|
2017-07-18 |
2023-01-23 |
国立大学法人京都大学 |
Gene mutation introduction method
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
BR102017016440A2
(en)
|
2017-07-31 |
2019-03-19 |
Universidade Federal Do Rio Grande Do Sul |
COMPOSITION FOR CENTRAL NERVOUS SYSTEM GENE THERAPY, OBTAINING AND USE PROCESS
|
BR112019027673A2
(en)
|
2017-07-31 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
non-human animal, and, methods to test the recombination induced by crispr / cas and to optimize the ability of crispr / cas
|
JP2020533957A
(en)
|
2017-07-31 |
2020-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
CRISPR Reporter Non-Human Animals and Their Use
|
KR20200032693A
(en)
*
|
2017-07-31 |
2020-03-26 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-transformed mouse embryonic stem cells and mice and uses thereof
|
WO2019040650A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
EP3681501A1
(en)
*
|
2017-09-15 |
2020-07-22 |
The Board of Trustees of the Leland Stanford Junior University |
Mitochondrial aldehyde dehydrogenase-2 modulators for protecting, expanding and increasing the potency of hematopoietic stem cells
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
JP7397488B2
(en)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
SOD1 dual expression vector and its use
|
CA3077307A1
(en)
|
2017-09-27 |
2019-04-04 |
Pioneer Hi-Bred International, Inc. |
Soil application of crop protection agents
|
WO2019066535A1
(en)
*
|
2017-09-28 |
2019-04-04 |
주식회사 탠덤 |
Novel recombinant plasma membrane-based vesicle, for treating cancer
|
AU2018338790B2
(en)
|
2017-09-29 |
2022-09-15 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TTR locus and methods of use
|
KR20200058509A
(en)
|
2017-09-29 |
2020-05-27 |
인텔리아 테라퓨틱스, 인크. |
Composition and method for TTR gene editing and treatment of ATTR amyloidosis
|
AU2018346530A1
(en)
|
2017-10-04 |
2020-04-30 |
Massachusetts Institute Of Technology |
CRISPR effector system based diagnostics
|
EP3692152A4
(en)
|
2017-10-04 |
2021-12-01 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
US11680296B2
(en)
|
2017-10-16 |
2023-06-20 |
Massachusetts Institute Of Technology |
Mycobacterium tuberculosis host-pathogen interaction
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
EP3697895A4
(en)
|
2017-10-20 |
2021-12-08 |
Fred Hutchinson Cancer Research Center |
Systems and methods to produce b cells genetically modified to express selected antibodies
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
WO2019099943A1
(en)
|
2017-11-16 |
2019-05-23 |
Astrazeneca Ab |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
EP3725092A4
(en)
|
2017-12-14 |
2021-09-22 |
FloDesign Sonics, Inc. |
Acoustic transducer drive and controller
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
BR112020014168A2
(en)
|
2018-01-12 |
2020-12-08 |
Basf Se |
PROTEIN, ISOLATED NUCLEIC ACID, RECOMBINANT GENE, VECTOR, HOSTING CELL, PLANT, PART OF PLANT OR WHEAT SEED, METHODS OF PRODUCTION, WHEAT PRODUCT, FLOUR, WHOLE MUSHROOM, STARCH, MUSHROOMS AND MUSHROOMS. AND / OR SELECTING A WHEAT PLANT
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
BR112020013626A2
(en)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
quinoxalinone compounds, compositions, methods and kits to increase genome editing efficiency
|
EA202091708A1
(en)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
DNA PC INHIBITORS
|
BR112020015093A2
(en)
|
2018-01-29 |
2020-12-08 |
The Broad Institute, Inc. |
DIAGNOSIS BASED ON THE CRISPR EFFECTOR SYSTEM
|
CN112203676A
(en)
*
|
2018-02-02 |
2021-01-08 |
宾州研究基金会 |
Methods and materials for treating brain injury
|
EP3735248A4
(en)
*
|
2018-02-09 |
2021-11-17 |
Empirico Inc. |
Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
|
US20210054370A1
(en)
*
|
2018-02-27 |
2021-02-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for treating angelman syndrome
|
AU2019236210A1
(en)
|
2018-03-14 |
2020-09-10 |
Arbor Biotechnologies, Inc. |
Novel CRISPR DNA targeting enzymes and systems
|
KR101889683B1
(en)
*
|
2018-03-14 |
2018-08-17 |
유병탁 |
Constructing method for steel frame structure
|
WO2019178428A1
(en)
|
2018-03-14 |
2019-09-19 |
Arbor Biotechnologies, Inc. |
Novel crispr dna and rna targeting enzymes and systems
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
KR102647714B1
(en)
|
2018-03-19 |
2024-03-18 |
리제너론 파마슈티칼스 인코포레이티드 |
Transcriptional regulation in animals using the CRISPR/Cas system
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
WO2019204378A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
US20210071240A1
(en)
|
2018-04-19 |
2021-03-11 |
Massachusetts Institute Of Technology |
Single-stranded break detection in double-stranded dna
|
HUE059223T2
(en)
|
2018-04-24 |
2022-10-28 |
Kws Saat Se & Co Kgaa |
Plants with improved digestibility and marker haplotypes
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210147831A1
(en)
|
2018-04-27 |
2021-05-20 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
EP3787693A4
(en)
*
|
2018-04-30 |
2022-03-09 |
Oregon Health & Science University |
Methods of gene therapy
|
US11980507B2
(en)
|
2018-05-02 |
2024-05-14 |
Augmedics Ltd. |
Registration of a fiducial marker for an augmented reality system
|
WO2019213626A1
(en)
*
|
2018-05-03 |
2019-11-07 |
President And Fellows Of Harvard College |
In vivo homology directed repair in heart, skeletal muscle, and muscle stem cells
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
EP3794130A4
(en)
|
2018-05-16 |
2022-07-27 |
Synthego Corporation |
Methods and systems for guide rna design and use
|
US20210198664A1
(en)
|
2018-05-16 |
2021-07-01 |
Arbor Biotechnologies, Inc. |
Novel crispr-associated systems and components
|
CN108707628B
(en)
*
|
2018-05-28 |
2021-11-23 |
上海海洋大学 |
Preparation method of zebra fish notch2 gene mutant
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
GB201809588D0
(en)
*
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
US20210147915A1
(en)
|
2018-06-26 |
2021-05-20 |
The Broad Institute, Inc. |
Crispr/cas and transposase based amplification compositions, systems and methods
|
SG11202012786RA
(en)
|
2018-06-26 |
2021-01-28 |
Massachusetts Inst Technology |
Crispr effector system based amplification methods, systems, and diagnostics
|
AU2019291827A1
(en)
|
2018-06-26 |
2020-12-24 |
Massachusetts Institute Of Technology |
Crispr double nickase based amplification compositions, systems, and methods
|
US11629179B2
(en)
|
2018-06-29 |
2023-04-18 |
Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis |
TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
|
US20210285009A1
(en)
|
2018-07-13 |
2021-09-16 |
The Regents Of The University Of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
US20210284981A1
(en)
*
|
2018-07-24 |
2021-09-16 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
AU2019314433A1
(en)
|
2018-07-31 |
2021-03-25 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
GB201812603D0
(en)
|
2018-08-02 |
2018-09-19 |
British American Tobacco Investments Ltd |
Method
|
EP3833761A1
(en)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
KR102103103B1
(en)
*
|
2018-08-16 |
2020-04-21 |
(주)라트바이오 |
Transgenic animals and transgenic embryos producing an engineered nuclease
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
EP3847650A1
(en)
|
2018-09-06 |
2021-07-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
CA3113095A1
(en)
|
2018-09-18 |
2020-03-26 |
Vnv Newco Inc. |
Arc-based capsids and uses thereof
|
US20210396756A1
(en)
|
2018-10-03 |
2021-12-23 |
The Broad Institute, Inc. |
Crispr effector system based diagnostics for hemorrhagic fever detection
|
WO2020077135A1
(en)
|
2018-10-10 |
2020-04-16 |
Dana-Farber Cancer Institute, Inc. |
Modulating resistance to bcl-2 inhibitors
|
US20220411783A1
(en)
|
2018-10-12 |
2022-12-29 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
CN109295081B
(en)
*
|
2018-10-17 |
2020-06-12 |
中国人民解放军第四军医大学 |
LDLR-Lamp2b fusion gene, expression vector and application thereof
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
GB201817971D0
(en)
|
2018-11-02 |
2018-12-19 |
British American Tobacco Investments Ltd |
Method
|
CN113832185A
(en)
*
|
2018-11-13 |
2021-12-24 |
四川横竖生物科技股份有限公司 |
Vector and reagent for constructing hNPY and hAGRP gene overexpression chimeric animal model and application
|
KR20210104698A
(en)
|
2018-11-14 |
2021-08-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Droplet diagnosis system and method based on CRISPR system
|
BR112021009441A2
(en)
|
2018-11-14 |
2021-11-23 |
Massachusetts Inst Technology |
Multiplexing highly evolving viral variants with Sherlock
|
GB201818715D0
(en)
|
2018-11-16 |
2019-01-02 |
British American Tobacco Investments Ltd |
Method
|
US11766296B2
(en)
|
2018-11-26 |
2023-09-26 |
Augmedics Ltd. |
Tracking system for image-guided surgery
|
WO2020118110A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Fred Hutchinson Cancer Research Center |
Reduced and minimal manipulation manufacturing of genetically-modified cells
|
KR20200071198A
(en)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Development of new adoptive T cell immunotherapy by modification of Nrf2 expression
|
WO2020124050A1
(en)
|
2018-12-13 |
2020-06-18 |
The Broad Institute, Inc. |
Tiled assays using crispr-cas based detection
|
WO2020123887A2
(en)
|
2018-12-14 |
2020-06-18 |
Pioneer Hi-Bred International, Inc. |
Novel crispr-cas systems for genome editing
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
JP7449291B2
(en)
|
2018-12-20 |
2024-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Nuclease-mediated repeat expansion
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
US20220064635A1
(en)
*
|
2019-01-07 |
2022-03-03 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of adenosine deaminase 2 (ada2)
|
US11116778B2
(en)
|
2019-01-15 |
2021-09-14 |
Empirico Inc. |
Prodrugs of ALOX-15 inhibitors and methods of using the same
|
GB201900940D0
(en)
|
2019-01-23 |
2019-03-13 |
British American Tobacco Investments Ltd |
Method
|
US20220119871A1
(en)
|
2019-01-28 |
2022-04-21 |
The Broad Institute, Inc. |
In-situ spatial transcriptomics
|
US11965159B2
(en)
|
2019-01-29 |
2024-04-23 |
The Broad Institute, Inc. |
Compositions and methods for regulating proteins and nucleic acids activities
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
US20220145330A1
(en)
|
2019-02-10 |
2022-05-12 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Modified mitochondrion and methods of use thereof
|
WO2020168075A1
(en)
*
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
|
CN116497067A
(en)
|
2019-02-13 |
2023-07-28 |
比姆医疗股份有限公司 |
Compositions and methods for treating heme lesions
|
WO2020172343A2
(en)
|
2019-02-19 |
2020-08-27 |
Massachusetts Institute Of Technology |
Methods for treating injuries
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
CA3129744A1
(en)
|
2019-03-12 |
2020-09-17 |
Emmanuelle CHARPENTIER |
Cas9 variants with enhanced specificity
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020186237A1
(en)
|
2019-03-13 |
2020-09-17 |
The Broad Institute, Inc. |
Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
|
WO2020186235A1
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
US20220154258A1
(en)
|
2019-03-14 |
2022-05-19 |
The Broad Institute, Inc. |
Crispr effector system based multiplex diagnostics
|
WO2020186223A1
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Sherlock assays for tick-borne diseases
|
WO2020186213A1
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
WO2020190932A1
(en)
|
2019-03-18 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
ES2969026T3
(en)
|
2019-03-18 |
2024-05-16 |
Regeneron Pharma |
CRISPR/CAS dropout detection platform to reveal genetic vulnerabilities associated with tau aggregation
|
WO2020191069A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
EP3942040A1
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN111733225A
(en)
*
|
2019-03-25 |
2020-10-02 |
北京大学第一医院 |
PRKG1 gene SNP marker for assisting accurate medication of clopidogrel
|
WO2020205681A1
(en)
|
2019-03-29 |
2020-10-08 |
Massachusetts Institute Of Technology |
Constructs for continuous monitoring of live cells
|
US20220175848A1
(en)
|
2019-04-01 |
2022-06-09 |
The Broad Institute, Inc. |
Methods and compositions for cell therapy
|
WO2020206036A1
(en)
|
2019-04-01 |
2020-10-08 |
The Broad Institute, Inc. |
Novel nucleic acid modifier
|
US20200318136A1
(en)
|
2019-04-03 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
CN113795588A
(en)
|
2019-04-04 |
2021-12-14 |
瑞泽恩制药公司 |
Methods for scar-free introduction of targeted modifications in targeting vectors
|
SG11202108454RA
(en)
|
2019-04-04 |
2021-09-29 |
Regeneron Pharma |
Non-human animals comprising a humanized coagulation factor 12 locus
|
US20220213469A1
(en)
|
2019-04-30 |
2022-07-07 |
The Broad Institute, Inc. |
Methods and compositions for barcoding nucleic acid libraries and cell populations
|
MX2021013400A
(en)
*
|
2019-05-03 |
2022-04-20 |
Specific Biologics Inc |
Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing.
|
US20230190819A1
(en)
*
|
2019-05-11 |
2023-06-22 |
Youngsuk Yi |
Compositions and methods containing exosomes
|
US20220243287A1
(en)
|
2019-05-13 |
2022-08-04 |
KWS SAAT SE & Co. KGaA |
Drought tolerance in corn
|
GB201906768D0
(en)
|
2019-05-14 |
2019-06-26 |
British American Tobacco Investments Ltd |
Method
|
US20220249701A1
(en)
|
2019-05-14 |
2022-08-11 |
The Broad Institute, Inc. |
Compositions and methods for targeting multinucleated cells
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
JP2022534202A
(en)
*
|
2019-05-21 |
2022-07-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Expression vectors for cholesterol 24-hydrolase in the treatment of Rett syndrome
|
AR118995A1
(en)
|
2019-05-25 |
2021-11-17 |
Kws Saat Se & Co Kgaa |
HAPLOID INDUCTION ENHANCER
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
CN112005960B
(en)
*
|
2019-05-31 |
2022-10-21 |
武汉科技大学 |
Automatic pregnant mother mouse breeding method
|
KR20220016869A
(en)
|
2019-06-04 |
2022-02-10 |
리제너론 파마슈티칼스 인코포레이티드 |
Non-Human Animals Comprising a Humanized TTR Locus with Beta-Slip Mutations and Methods of Use
|
MX2021015122A
(en)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus.
|
JP2022536606A
(en)
|
2019-06-14 |
2022-08-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Model of tauopathy
|
WO2020257514A1
(en)
*
|
2019-06-21 |
2020-12-24 |
Children's Medical Center Corporation |
Methods and compositions for allele specific gene editing
|
AU2020298572A1
(en)
|
2019-07-02 |
2021-11-18 |
Fred Hutchinson Cancer Center |
Recombinant Ad35 vectors and related gene therapy improvements
|
GB201909562D0
(en)
|
2019-07-03 |
2019-08-14 |
British American Tobacco Investments Ltd |
Method
|
GB201909563D0
(en)
|
2019-07-03 |
2019-08-14 |
British American Tobacco Investments Ltd |
Method
|
US11980506B2
(en)
|
2019-07-29 |
2024-05-14 |
Augmedics Ltd. |
Fiducial marker
|
EP3772542A1
(en)
|
2019-08-07 |
2021-02-10 |
KWS SAAT SE & Co. KGaA |
Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021046257A1
(en)
|
2019-09-03 |
2021-03-11 |
The Broad Institute, Inc. |
Crispr effector system based multiplex cancer diagnostics
|
JP2022547570A
(en)
|
2019-09-12 |
2022-11-14 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Engineered adeno-associated virus capsid
|
CA3153980A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
EP4031660A1
(en)
|
2019-09-20 |
2022-07-27 |
The Broad Institute, Inc. |
Novel type vi crispr enzymes and systems
|
US20220389451A1
(en)
|
2019-09-20 |
2022-12-08 |
The Broad Institute, Inc. |
Compositions and methods for delivering cargo to a target cell
|
GB201913974D0
(en)
*
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
WO2021074367A1
(en)
|
2019-10-17 |
2021-04-22 |
KWS SAAT SE & Co. KGaA |
Enhanced disease resistance of crops by downregulation of repressor genes
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
BR112022008861A2
(en)
|
2019-11-08 |
2022-08-23 |
Regeneron Pharma |
NUCLEIC ACID CONSTRUCTION, VECTOR, LIPID NANO PARTICLE, CELL, COMPOSITION FOR USE IN EXPRESSING RETINOSCHISIN, METHOD FOR INTEGRATING A CODING SEQUENCE, AND, METHOD FOR MODIFYING AN RS1 GENE
|
CN110684801A
(en)
*
|
2019-11-13 |
2020-01-14 |
武汉华美生物工程有限公司 |
Method for gene editing by transducing cas9 gene into mammalian cell
|
AU2020388387A1
(en)
|
2019-11-22 |
2022-06-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
EP3835309A1
(en)
|
2019-12-13 |
2021-06-16 |
KWS SAAT SE & Co. KGaA |
Method for increasing cold or frost tolerance in a plant
|
US11382712B2
(en)
|
2019-12-22 |
2022-07-12 |
Augmedics Ltd. |
Mirroring in image guided surgery
|
JP2023508362A
(en)
*
|
2019-12-23 |
2023-03-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
|
IL294715A
(en)
|
2020-01-23 |
2022-09-01 |
Childrens Medical Ct Corp |
Stroma-free t cell differentiation from human pluripotent stem cells
|
EP3872190A1
(en)
|
2020-02-26 |
2021-09-01 |
Antibodies-Online GmbH |
A method of using cut&run or cut&tag to validate crispr-cas targeting
|
KR20240035924A
(en)
*
|
2020-02-28 |
2024-03-18 |
후이진 테라퓨틱스 씨오., 엘티디. |
Type vi-e and type vi-f crispr-cas system and uses thereof
|
CN115485385A
(en)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
Methods and compositions for sensitizing tumor cells to immunotherapy
|
CN111321150B
(en)
*
|
2020-03-13 |
2020-12-04 |
广西壮族自治区水产科学研究院 |
LvCTL4 gene, encoded protein, protein acquisition method, expression vector, recombinant bacterium and application
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US11851702B2
(en)
|
2020-03-23 |
2023-12-26 |
The Broad Institute, Inc. |
Rapid diagnostics
|
BR112022019713A2
(en)
|
2020-03-31 |
2022-12-20 |
Arbor Biotechnologies Inc |
COMPOSITIONS COMPRISING A CAS12I2 VARIANT POLYPEPTIDE AND USES THEREOF
|
WO2021202938A1
(en)
|
2020-04-03 |
2021-10-07 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
WO2021205000A2
(en)
|
2020-04-09 |
2021-10-14 |
R.J. Reynolds Tobacco Company |
Method
|
WO2021211734A1
(en)
*
|
2020-04-15 |
2021-10-21 |
The Regents Of The University Of California |
Compositions and methods for treatment
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
WO2021224633A1
(en)
|
2020-05-06 |
2021-11-11 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
MX2022014008A
(en)
|
2020-05-08 |
2023-02-09 |
Broad Inst Inc |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence.
|
CN111521826A
(en)
*
|
2020-05-21 |
2020-08-11 |
江海松 |
Application of Notch3 protein in peripheral blood exosome as molecular marker and detection kit
|
CN116782762A
(en)
|
2020-05-29 |
2023-09-19 |
科沃施种子欧洲股份两合公司 |
Plant haploid induction
|
WO2022010286A1
(en)
*
|
2020-07-08 |
2022-01-13 |
경상국립대학교산학협력단 |
Donor nucleic acid used for gene correction through microhomology-mediated end joining and uses thereof
|
US20230321278A1
(en)
*
|
2020-07-10 |
2023-10-12 |
President And Fellows Of Harvard College |
Aav vector delivery systems
|
CN111979241B
(en)
*
|
2020-07-23 |
2021-10-01 |
上海市第一人民医院 |
Method for preparing non-human mammal model of retinitis pigmentosa
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
AU2021338707A1
(en)
|
2020-09-10 |
2023-04-06 |
Monsanto Technology Llc |
Increasing gene editing and site-directed integration events utilizing meiotic and germline promoters
|
CN112159809B
(en)
*
|
2020-09-22 |
2021-06-22 |
广州瑞风生物科技有限公司 |
gRNA of target CTGF gene and application thereof
|
WO2022068912A1
(en)
|
2020-09-30 |
2022-04-07 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
WO2022188039A1
(en)
|
2021-03-09 |
2022-09-15 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
RU2749307C1
(en)
*
|
2020-10-30 |
2021-06-08 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
New compact type ii cas9 nuclease from anoxybacillus flavithermus
|
EP4001429A1
(en)
|
2020-11-16 |
2022-05-25 |
Antibodies-Online GmbH |
Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
IL305030A
(en)
|
2021-02-11 |
2023-10-01 |
Arbor Biotechnologies Inc |
Compositions comprising a variant cas12i4 polypeptide and uses thereof
|
CN112997966A
(en)
*
|
2021-03-08 |
2021-06-22 |
国家卫生健康委科学技术研究所 |
Mouse model knocking-in miRNA-125a based on CRISPR/Cas9 technology and construction method
|
WO2022188797A1
(en)
|
2021-03-09 |
2022-09-15 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
WO2022204543A1
(en)
*
|
2021-03-25 |
2022-09-29 |
The Regents Of The University Of California |
Methods and materials for treating huntington's disease
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
CN113180015A
(en)
*
|
2021-05-25 |
2021-07-30 |
四川省农业机械研究设计院 |
Silkworm rearing room and three-section type assembly line silkworm rearing method
|
EP4349979A1
(en)
|
2021-05-27 |
2024-04-10 |
Institute Of Zoology, Chinese Academy Of Sciences |
Engineered cas12i nuclease, effector protein and use thereof
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4355351A1
(en)
*
|
2021-06-18 |
2024-04-24 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified cells targeting tumor ecm and therapy thereof
|
US11896445B2
(en)
|
2021-07-07 |
2024-02-13 |
Augmedics Ltd. |
Iliac pin and adapter
|
CA3225121A1
(en)
|
2021-07-20 |
2023-01-26 |
Benjamin DEVERMAN |
Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
|
US20230048564A1
(en)
|
2021-07-22 |
2023-02-16 |
Arbor Biotechnologies, Inc. |
Crispr-associated transposon systems and methods of using same
|
CA3221517A1
(en)
|
2021-07-30 |
2023-02-02 |
Monika KLOIBER-MAITZ |
Plants with improved digestibility and marker haplotypes
|
CN113607963B
(en)
*
|
2021-08-11 |
2024-05-24 |
河南省人民医院 |
Protein marker for predicting retinal aging process, screening method and application thereof
|
EP4384608A1
(en)
|
2021-08-12 |
2024-06-19 |
Arbor Biotechnologies, Inc. |
Compositions comprising a variant cas12i3 polypeptide and uses thereof
|
CN113373178A
(en)
*
|
2021-08-13 |
2021-09-10 |
上海南方模式生物科技股份有限公司 |
Construction method and application of TLR8 gene humanized animal model
|
JP7125727B1
(en)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
Compositions for modifying nucleic acid sequences and methods for modifying target sites in nucleic acid sequences
|
CA3230927A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023059846A1
(en)
|
2021-10-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
IL311962A
(en)
|
2021-10-14 |
2024-06-01 |
Lonza Sales Ag |
Modified producer cells for extracellular vesicle production
|
CN113913428A
(en)
*
|
2021-10-14 |
2022-01-11 |
南通大学 |
Small interfering RNA of targeting Tap 2a gene and application thereof in preparation of medicine for treating chronic pain
|
CN118251491A
(en)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
CRISPR/Cas related methods and compositions for knockout of C5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(en)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
Novel CRISPR-Cas12i system
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023093862A1
(en)
|
2021-11-26 |
2023-06-01 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
CN114107231B
(en)
*
|
2021-12-13 |
2023-08-18 |
重庆大学 |
Recombinant adeno-associated virus for realizing whole brain postsynaptic neuron cell body marking and application thereof
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
TW202342757A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae attachment glycoproteins
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
CN114280300B
(en)
*
|
2021-12-28 |
2023-04-25 |
四川大学华西医院 |
Application of urine protein in diagnosis of metabolic liver disease
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
TW202332767A
(en)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150637A1
(en)
|
2022-02-02 |
2023-08-10 |
Inscripta, Inc. |
Nucleic acid-guided nickase fusion proteins
|
WO2023148478A1
(en)
|
2022-02-03 |
2023-08-10 |
Nicoventures Trading Limited |
Method of modulating alkaloid content in tobacco plants
|
WO2023148476A1
(en)
|
2022-02-03 |
2023-08-10 |
Nicoventures Trading Limited |
Method of modulating alkaloid content in tobacco plants
|
WO2023148475A1
(en)
|
2022-02-04 |
2023-08-10 |
Nicoventures Trading Limited |
Method of modulating alkaloid content in tobacco plants
|
CN114480497B
(en)
*
|
2022-02-28 |
2023-09-15 |
湖南师范大学 |
Construction and application method of ep400 gene knockout zebra fish heart failure model
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
GB202205148D0
(en)
|
2022-04-07 |
2022-05-25 |
Nicoventures Trading Ltd |
Method
|
GB202205149D0
(en)
|
2022-04-07 |
2022-05-25 |
Nicoventures Trading Ltd |
Method
|
GB202205562D0
(en)
|
2022-04-14 |
2022-06-01 |
Nicoventures Trading Ltd |
Method
|
GB202205561D0
(en)
|
2022-04-14 |
2022-06-01 |
Nicoventures Trading Ltd |
Method
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
GB202206109D0
(en)
|
2022-04-27 |
2022-06-08 |
Nicoventures Trading Ltd |
Method
|
GB202206107D0
(en)
|
2022-04-27 |
2022-06-08 |
Nicoventures Trading Ltd |
Method
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023225564A1
(en)
|
2022-05-18 |
2023-11-23 |
The Broad Institute, Inc. |
Engineered viral capsids with increased stability and methods of use thereof
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
CN115053861A
(en)
*
|
2022-06-30 |
2022-09-16 |
南方医科大学南方医院 |
Construction method and application of animal model of schizophrenia based on immune activation
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020557A1
(en)
|
2022-07-22 |
2024-01-25 |
Arbor Biotechnologies, Inc. |
Compositions comprising a variant nuclease and uses thereof
|
WO2024020567A1
(en)
|
2022-07-22 |
2024-01-25 |
Arbor Biotechnologies, Inc. |
Compositions comprising a variant polypeptide and uses thereof
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
CN115109799A
(en)
*
|
2022-07-26 |
2022-09-27 |
华中科技大学同济医学院附属协和医院 |
Fusion plasmid of small molecular peptide and application of fusion plasmid in antitumor drugs
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
CN115247149B
(en)
*
|
2022-08-22 |
2023-06-16 |
华域生物科技(天津)有限公司 |
Culture medium composition suitable for NK cells and culture method
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042199A1
(en)
|
2022-08-26 |
2024-02-29 |
KWS SAAT SE & Co. KGaA |
Use of paired genes in hybrid breeding
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|